| 1 |
Sonoda H, Yamada T, Matsuda A, Yokoyama Y, Ohta R, Shinji S, Yonaga K, Iwai T, Takeda K, Ueda K, Kuriyama S, Miyasaka T, Kanaka S, Taniai N, Yoshida H. The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage II-III colorectal cancer. Surg Today 2023. [PMID: 36707435 DOI: 10.1007/s00595-023-02644-6] [Reference Citation Analysis]
|
| 2 |
Sun Z, Zhong J, Lu J, Si L, Pan X, He K, Wang Q, Zhang Y, Bao J. The kinetics of circulating cell-free DNA to predict the clinical efficacy of first-line chemotherapy in patients with metastatic colorectal cancer.. [DOI: 10.21203/rs.3.rs-2018900/v1] [Reference Citation Analysis]
|
| 3 |
Ueda K, Yamada T, Ohta R, Matsuda A, Sonoda H, Kuriyama S, Takahashi G, Iwai T, Takeda K, Miyasaka T, Shinji S, Chika N, Ishida H, Yoshida H. BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.01.016] [Reference Citation Analysis]
|
| 4 |
Snyder RA, Dasari A, You YN. Liquid Biopsy. Colorectal Liver Metastasis 2022. [DOI: 10.1007/978-3-031-09323-4_49] [Reference Citation Analysis]
|
| 5 |
Marsh RDW. Immunotherapy. Colorectal Liver Metastasis 2022. [DOI: 10.1007/978-3-031-09323-4_35] [Reference Citation Analysis]
|
| 6 |
Callesen LB, Takacova T, Hamfjord J, Würschmidt F, Oldhafer KJ, Brüning R, Arnold D, Spindler KG. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis. Ther Adv Med Oncol 2022;14:17588359221133171. [PMID: 36339929 DOI: 10.1177/17588359221133171] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Chen X, Du Z, Huang M, Wang D, Fong WP, Liang J, Fan L, Wang Y, Yang H, Chen Z, Hu M, Xu R, Li Y. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. Cancer Immunol Immunother 2021. [PMID: 34322779 DOI: 10.1007/s00262-021-03021-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 8 |
Takemasa I, Hamabe A, Ishii M. Perspectives for circulating tumor DNA in clinical management of colorectal cancer. Int J Clin Oncol 2021;26:1420-30. [PMID: 34185174 DOI: 10.1007/s10147-021-01937-5] [Reference Citation Analysis]
|
| 9 |
Sonoda H, Yamada T, Matsuda A, Ohta R, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Ueda K, Kuriyama S, Miyasaka T, Yoshida H. Elevated serum carcinoembryonic antigen level after curative surgery is a prognostic biomarker of stage II-III colorectal cancer. Eur J Surg Oncol 2021:S0748-7983(21)00536-9. [PMID: 34103245 DOI: 10.1016/j.ejso.2021.05.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 10 |
Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Target Oncol 2021;16:309-24. [PMID: 33738696 DOI: 10.1007/s11523-021-00795-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 11 |
Ko K, Kananazawa Y, Yamada T, Kakinuma D, Matsuno K, Ando F, Kuriyama S, Matsuda A, Yoshida H. Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer. Cancer Med 2021;10:2003-12. [PMID: 33641249 DOI: 10.1002/cam4.3755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Kolenčík D, Shishido SN, Pitule P, Mason J, Hicks J, Kuhn P. Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. Cancers (Basel) 2020;12:E1376. [PMID: 32471160 DOI: 10.3390/cancers12061376] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 13 |
Yamada T, Matsuda A, Takahashi G, Iwai T, Takeda K, Ueda K, Kuriyama S, Koizumi M, Shinji S, Yokoyama Y, Ohta R, Yoshida H. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. Int J Clin Oncol 2020;25:1523-32. [PMID: 32394048 DOI: 10.1007/s10147-020-01691-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
|
